Eleven biopharmaceutical companies have gone public in the US in July, raising $2.38bn through initial public offerings, including four IPOs on 24 July from Annexon Biosciences, iTeos Therapeutics Inc., Inozyme Pharma Inc. and Nurix Therapeutics, Inc.
Drug developers have successfully raised large sums of money in the US stock market despite the global economic uncertainty associated...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?